Performant Healthcare Azioni (NASDAQ: PHLT)

Performant Healthcare (NASDAQ:PHLT) Azioni

Performant Healthcare

Performant Healthcare Inc provides solutions to payers in the healthcare industry to identify, prevent, and recover waste and improper payments by leveraging technology, analytics, and proprietary data assets.

Performant Healthcare, Inc. - Common Stock

Performant Healthcare Inc

Imagica Group Inc

News

Events

NVDA

Live On CNBC, Chyron Reads "Nvidia CEO Jensen Huang Met With President Trump Today At White House"

<p><strong>Lucid Group, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares are trading lower Wednesday after the company reported worse-than-<a href="https://www.benzinga.com/node/46872160">expected financial results</a>.</p>
<p><strong>What To Know:</strong> Lucid reported an adjusted loss of 24 cents per share, missing estimates for a loss of 21 cents. In addition, the company reported sales of $259.43 million, missing the consensus estimate of $296.24 million.</p>
<p>Lucid delivered 3,309 vehicles in the second quarter, marking a 38% increase year-over-year and its sixth consecutive quarter of record deliveries. The company produced 3,863 vehicles during the quarter and ended the period with approximately $4.86 billion in total liquidity.</p>
<p>Despite those gains, Lucid revised its full-year production outlook, lowering guidance to a range of 18,000 to 20,000 vehicles from its previous target of 20,000. Leadership said the change reflects a dynamic macroeconomic environment and an emphasis on disciplined cost management. </p>
<p>Executives also reaffirmed the company's focus on ramping up production of the Lucid Gravity SUV in the second half of the year.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/markets/earnings/25/08/46899149/jim-cramer-says-tariffs-will-become-a-build-in-cost-for-companies-as-caterpillar-takes-hit-amid-mixed-q2">Jim Cramer Says Tariffs Will Become A &#8216;Build-In Cost For Companies&#8217; As Caterpillar Takes Hit Amid Mixed Q2</a></strong></p>
<p><strong>LCID Price Action: </strong>At the time of publication, Lucid stock is trading 8.85% lower at $2.20, according to data from<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro</a>.</p>
<p><em>Image via Shutterstock</em></p>


Movers

LCID

Lucid Stock Is Falling Wednesday: What's Going On?

<p>Shares of<strong> The New York Times Company </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYT#NYSE">NYT</a>) are trading higher Wednesday after the media company reported better-than-expected <a href="https://www.benzinga.com/pressreleases/25/08/b46891665/the-new-york-times-company-reports-second-quarter-2025-results">second-quarter earnings and revenue. </a></p>
<p><strong>What To Know</strong>: <a href="https://www.nytco.com/investors/">The results </a>were driven by growth across digital subscriptions, advertising, and licensing revenues, with improvements in profitability adding further investor confidence.</p>
<p>Adjusted earnings per share came in at 58 cents, beating analyst expectations of 50 cents and up from 45 cents a year ago. Revenue for the quarter reached $685.87 million, surpassing the $670.74 million consensus estimate and marking a nearly 10% increase year-over-year.</p>
<p>The company added approximately 230,000 net digital-only subscribers during the quarter, bringing its total to 11.88 million. Average revenue per user for digital-only subscriptions rose 3.2% to $9.64, driven by pricing changes and the expiration of promotional offers. </p>
<p>Digital subscription revenue increased 15.1% compared to the prior year, while digital advertising revenue rose 18.7%, supported by stronger demand across newer advertising segments. Licensing and affiliate revenues also saw modest gains.</p>
<p>Commenting on the results, CEO <strong>Meredith Kopit</strong> Levien said, "We had a great second quarter across the board, and our strategy continues to work as designed. We grew all of our major revenue lines and we're generating significant free cash flow." She added that a strong balance sheet and ongoing investment in journalism and product development will continue to drive long-term profitability.</p>
<p><strong>NYT Price Action:</strong> The new york times shares were up 15.8% at $62.12 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/08/46908946/fed-rate-cut-september-kashkari-goldman-outlook-2025">Another Fed Official Backs A Rate Cut—Goldman Sees Trouble Ahead If The Fed Waits</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


New York Times Stock Jumps 15% After Strong Q2 Earnings Beat

<p>Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) will release its quarterly earnings report on Thursday, 2025-08-07. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Array Technologies to report an <strong>earnings per share</strong> (EPS) of $0.19.</p>
<p>Array Technologies bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.04, leading to a 2.14% drop in the share price on the subsequent day.</p>
<p>Here's a look at Array Technologies's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.09</td>
<td>0.17</td>
<td>0.14</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.13</td>
<td>0.16</td>
<td>0.17</td>
<td>0.20</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-19.0%</td>
<td>-3.0%</td>
<td>-21.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754507049_0.png" alt="eps graph" /></p>
<h3>Performance of Array Technologies Shares</h3>
<p>Shares of Array Technologies were trading at $5.91 as of August 05. Over the last 52-week period, shares are down 35.65%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ARRY/earnings"><strong>To track all earnings releases for Array Technologies visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

ARRY

Insights Ahead: Array Technologies's Quarterly Earnings

<p>Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) will release its quarterly earnings report on Thursday, 2025-08-07. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Arhaus to report an <strong>earnings per share</strong> (EPS) of $0.15.</p>
<p>The market awaits Arhaus's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS missed by $0.03 in the last quarter, leading to a 0.38% increase in the share price on the following day.</p>
<p>Here's a look at Arhaus's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.06</td>
<td>0.12</td>
<td>0.08</td>
<td>0.12</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.03</td>
<td>0.15</td>
<td>0.07</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>-14.000000000000002%</td>
<td>-0.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754507013_0.png" alt="eps graph" /></p>
<h3>Arhaus Share Price Analysis</h3>
<p>Shares of Arhaus were trading at $9.515 as of August 05. Over the last 52-week period, shares are down 18.6%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Insights on Arhaus</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Arhaus.</p>
<p>With 8 analyst ratings, Arhaus has a consensus rating of Neutral. The average one-year price target is $9.88, indicating a potential 3.84% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Beyond and Williams-Sonoma, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Beyond, with an average 1-year price target of $13.0, suggesting a potential 36.63% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Williams-Sonoma, with an average 1-year price target of $191.0, suggesting a potential 1907.36% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Beyond and Williams-Sonoma are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arhaus</td>
<td>Neutral</td>
<td>5.49%</td>
<td>$115.59M</td>
<td>1.41%</td>
</tr>
<tr>
<td>Beyond</td>
<td>Outperform</td>
<td>-29.10%</td>
<td>$66.97M</td>
<td>-14.08%</td>
</tr>
<tr>
<td>Williams-Sonoma</td>
<td>Outperform</td>
<td>4.20%</td>
<td>$765.81M</td>
<td>10.75%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Arhaus has the highest revenue growth among its peers. It has the lowest gross profit margin. Arhaus has the lowest return on equity compared to its peers.</p>
<h3>Delving into Arhaus's Background</h3>
<p>Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.</p>
<h3>A Deep Dive into Arhaus's Financials</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Arhaus's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>5.49%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Arhaus's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>1.57%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Arhaus's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.41%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Arhaus's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.4%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.5</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/ARHS/earnings"><strong>To track all earnings releases for Arhaus visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ARHS

Insights into Arhaus's Upcoming Earnings

<p>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) is preparing to release its quarterly earnings on Thursday, 2025-08-07. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Akebia Therapeutics to report an <strong>earnings per share</strong> (EPS) of $-0.02.</p>
<p>Anticipation surrounds Akebia Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.07 in the last quarter, leading to a 2.67% drop in the share price on the following day.</p>
<p>Here's a look at Akebia Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.04</td>
<td>-0.08</td>
<td>-0.06</td>
<td>-0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.03</td>
<td>-0.10</td>
<td>-0.10</td>
<td>-0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>34.0%</td>
<td>4.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754507005_0.png" alt="eps graph" /></p>
<h3>Akebia Therapeutics Share Price Analysis</h3>
<p>Shares of Akebia Therapeutics were trading at $3.72 as of August 05. Over the last 52-week period, shares are up 213.03%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/AKBA/earnings"><strong>To track all earnings releases for Akebia Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AKBA

Earnings Preview For Akebia Therapeutics

<p>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-08-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Performant Healthcare will report an <strong>earnings per share</strong> (EPS) of $-0.02.</p>
<p>Anticipation surrounds Performant Healthcare's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS beat by $0.04 in the last quarter, leading to a 10.67% increase in the share price on the following day.</p>
<p>Here's a look at Performant Healthcare's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.02</td>
<td>0</td>
<td>-0.03</td>
<td>-0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.02</td>
<td>0.02</td>
<td>-0.01</td>
<td>-0.03</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>11.0%</td>
<td>10.0%</td>
<td>-15.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506994_0.png" alt="eps graph" /></p>
<h3>Performance of Performant Healthcare Shares</h3>
<p>Shares of Performant Healthcare were trading at $7.62 as of August 05. Over the last 52-week period, shares are up 108.9%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Performant Healthcare</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Performant Healthcare.</p>
<p>Analysts have provided Performant Healthcare with 2 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $7.88, suggesting a potential 3.41% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Fulgent Genetics, AMN Healthcare Services and Nutex Health, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Fulgent Genetics, with an average 1-year price target of $25.5, suggesting a potential 234.65% upside.</li>
<li>Analysts currently favor an Neutral trajectory for AMN Healthcare Services, with an average 1-year price target of $25.5, suggesting a potential 234.65% upside.</li>
<li>Analysts currently favor an Buy trajectory for Nutex Health, with an average 1-year price target of $262.5, suggesting a potential 3344.88% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Fulgent Genetics, AMN Healthcare Services and Nutex Health, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Castle Biosciences</td>
<td>Outperform</td>
<td>-0.94%</td>
<td>$68.56M</td>
<td>1.01%</td>
</tr>
<tr>
<td>Fulgent Genetics</td>
<td>Buy</td>
<td>15.17%</td>
<td>$34.44M</td>
<td>-1.69%</td>
</tr>
<tr>
<td>AMN Healthcare Services</td>
<td>Neutral</td>
<td>-16.00%</td>
<td>$198.12M</td>
<td>-0.15%</td>
</tr>
<tr>
<td>Nutex Health</td>
<td>Buy</td>
<td>213.98%</td>
<td>$118.34M</td>
<td>8.52%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Performant Healthcare ranks at the bottom for Revenue Growth, with a negative growth rate compared to positive growth rates of its peers. It also lags behind in Gross Profit, having a lower figure than most peers. In terms of Return on Equity, Performant Healthcare is at the bottom with a negative percentage, while some peers have positive returns. Overall, Performant Healthcare is positioned lower compared to its peers across key financial metrics.</p>
<h3>Discovering Performant Healthcare: A Closer Look</h3>
<p>Performant Healthcare Inc provides solutions to payers in the healthcare industry to identify, prevent, and recover waste and improper payments by leveraging technology, analytics, and proprietary data assets.</p>
<h3>Performant Healthcare's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Performant Healthcare displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>21.71%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Performant Healthcare's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.24%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Performant Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-0.1%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-0.08%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Performant Healthcare's debt-to-equity ratio is below the industry average. With a ratio of <b>0.11</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/PHLT/earnings"><strong>To track all earnings releases for Performant Healthcare visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PHLT

A Preview Of Performant Healthcare's Earnings

<p>Pangaea Logistics Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANL#NASDAQ">PANL</a>) will release its quarterly earnings report on Thursday, 2025-08-07. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Pangaea Logistics Solns to report an <strong>earnings per share</strong> (EPS) of $-0.03.</p>
<p>The market awaits Pangaea Logistics Solns's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.09, which was followed by a 2.26% drop in the share price the next day.</p>
<p>Here's a look at Pangaea Logistics Solns's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.12</td>
<td>0.17</td>
<td>0.27</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.03</td>
<td>0.16</td>
<td>0.24</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>12.0%</td>
<td>-7.000000000000001%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506984_0.png" alt="eps graph" /></p>
<h3>Pangaea Logistics Solns Share Price Analysis</h3>
<p>Shares of Pangaea Logistics Solns were trading at $5.02 as of August 05. Over the last 52-week period, shares are down 23.16%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PANL/earnings"><strong>To track all earnings releases for Pangaea Logistics Solns visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PANL

Exploring Pangaea Logistics Solns's Earnings Expectations

<p>Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-08-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Vital Farms will report an <strong>earnings per share</strong> (EPS) of $0.27.</p>
<p>Vital Farms bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.10, leading to a 3.84% increase in the share price the following trading session.</p>
<p>Here's a look at Vital Farms's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.27</td>
<td>0.17</td>
<td>0.12</td>
<td>0.20</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.37</td>
<td>0.23</td>
<td>0.16</td>
<td>0.36</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>8.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506950_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Vital Farms were trading at $36.38 as of August 05. Over the last 52-week period, shares are up 16.56%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Vital Farms</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Vital Farms.</p>
<p>A total of 3 analyst ratings have been received for Vital Farms, with the consensus rating being Outperform. The average one-year price target stands at $45.67, suggesting a potential 25.54% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of WK Kellogg, Utz Brands and Treehouse Foods, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for WK Kellogg, with an average 1-year price target of $23.0, suggesting a potential 36.78% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Utz Brands, with an average 1-year price target of $15.5, suggesting a potential 57.39% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Treehouse Foods, with an average 1-year price target of $22.0, suggesting a potential 39.53% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>In the peer analysis summary, key metrics for WK Kellogg, Utz Brands and Treehouse Foods are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vital Farms</td>
<td>Outperform</td>
<td>9.64%</td>
<td>$62.51M</td>
<td>6.06%</td>
</tr>
<tr>
<td>WK Kellogg</td>
<td>Neutral</td>
<td>-6.22%</td>
<td>$189M</td>
<td>5.59%</td>
</tr>
<tr>
<td>Utz Brands</td>
<td>Neutral</td>
<td>2.95%</td>
<td>$126.80M</td>
<td>1.44%</td>
</tr>
<tr>
<td>Treehouse Foods</td>
<td>Neutral</td>
<td>1.20%</td>
<td>$139.20M</td>
<td>-0.19%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Vital Farms outperforms peers in revenue growth, ranking at the top. It also leads in gross profit margin. However, it falls behind in return on equity, placing in the middle among its peers.</p>
<h3>Get to Know Vital Farms Better</h3>
<p>Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter &amp; Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).</p>
<h3>Vital Farms: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Vital Farms's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>9.64%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Vital Farms's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>10.42%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Vital Farms's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>6.06%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Vital Farms's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>4.59%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Vital Farms's debt-to-equity ratio is below the industry average at <strong>0.07</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/VITL/earnings"><strong>To track all earnings releases for Vital Farms visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


VITL

Vital Farms Earnings Preview

<p>UWM Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-08-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that UWM Hldgs will report an <strong>earnings per share</strong> (EPS) of $0.06.</p>
<p>UWM Hldgs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.17, leading to a 0.25% increase in the share price the following trading session.</p>
<p>Here's a look at UWM Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.05</td>
<td>0.08</td>
<td>0.08</td>
<td>0.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.12</td>
<td>0.02</td>
<td>0.01</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506937_0.png" alt="eps graph" /></p>
<h3>Market Performance of UWM Hldgs's Stock</h3>
<p>Shares of UWM Hldgs were trading at $4.35 as of August 05. Over the last 52-week period, shares are down 49.76%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/UWMC/earnings"><strong>To track all earnings releases for UWM Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


UWMC

A Preview Of UWM Hldgs's Earnings

<p>High-rolling investors have positioned themselves bullish on Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in BROS often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for Dutch Bros. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 66% bullish and 33% bearish. Among all the options we identified, there was one put, amounting to $46,089, and 8 calls, totaling $347,297.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $51.0 to $70.0 for Dutch Bros during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Dutch Bros's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Dutch Bros's substantial trades, within a strike price spectrum from $51.0 to $70.0 over the preceding 30 days.</p>
<h3>Dutch Bros Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506926_0_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BROS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$6.8</td>
<td>$6.8</td>
<td>$6.8</td>
<td>$70.00</td>
<td>$61.2K</td>
<td>112</td>
<td align="right">90</td>
</tr>
<tr>
<td>BROS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$2.4</td>
<td>$2.35</td>
<td>$2.4</td>
<td>$64.00</td>
<td>$60.0K</td>
<td>1.2K</td>
<td align="right">3</td>
</tr>
<tr>
<td>BROS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$2.55</td>
<td>$2.35</td>
<td>$2.4</td>
<td>$67.50</td>
<td>$46.1K</td>
<td>1.8K</td>
<td align="right">261</td>
</tr>
<tr>
<td>BROS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$2.15</td>
<td>$1.85</td>
<td>$1.85</td>
<td>$51.00</td>
<td>$46.0K</td>
<td>50</td>
<td align="right">2</td>
</tr>
<tr>
<td>BROS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/08/25</td>
<td>$3.4</td>
<td>$3.2</td>
<td>$3.4</td>
<td>$61.00</td>
<td>$43.8K</td>
<td>174</td>
<td align="right">165</td>
</tr>
</tbody>
</table>
</p>
<h3>About Dutch Bros</h3>
<p>Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.</p>
<p>After a thorough review of the options trading surrounding Dutch Bros, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Dutch Bros</h3>
<ul>
<li>Trading volume stands at 2,808,748, with BROS's price up by 1.36%, positioned at $58.23.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>What The Experts Say On Dutch Bros</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $84.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Dutch Bros with a target price of $84. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Dutch Bros with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

BROS

This Is What Whales Are Betting On Dutch Bros

<p>TripAdvisor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-08-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that TripAdvisor will report an <strong>earnings per share</strong> (EPS) of $0.33.</p>
<p>The announcement from TripAdvisor is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.08, which was followed by a 4.04% increase in the share price the next day.</p>
<p>Here's a look at TripAdvisor's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.06</td>
<td>0.21</td>
<td>0.44</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.14</td>
<td>0.30</td>
<td>0.50</td>
<td>0.39</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-8.0%</td>
<td>-11.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506926_0.png" alt="eps graph" /></p>
<h3>Tracking TripAdvisor's Stock Performance</h3>
<p>Shares of TripAdvisor were trading at $16.23 as of August 05. Over the last 52-week period, shares are up 17.07%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about TripAdvisor</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding TripAdvisor.</p>
<p>TripAdvisor has received a total of 6 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $16.38, the consensus suggests a potential 0.92% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of  and Tripadvisor, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<h3>Peer Metrics Summary</h3>
<p>In the peer analysis summary, key metrics for  and Tripadvisor are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tripadvisor</td>
<td>Neutral</td>
<td>0.76%</td>
<td>$371M</td>
<td>-1.39%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Tripadvisor ranks in the middle among its peers for consensus rating. It is at the bottom for revenue growth. It is at the top for gross profit. It is at the bottom for return on equity.</p>
<h3>All You Need to Know About TripAdvisor</h3>
<p>Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).</p>
<h3>TripAdvisor: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> TripAdvisor displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>0.76%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Communication Services sector.</p>
<p><strong>Net Margin:</strong> TripAdvisor's net margin is impressive, surpassing industry averages. With a net margin of <strong>-2.76%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> TripAdvisor's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-1.39%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> TripAdvisor's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.41%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> TripAdvisor's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.97</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/TRIP/earnings"><strong>To track all earnings releases for TripAdvisor visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TRIP

Insights Ahead: TripAdvisor's Quarterly Earnings

<p>Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) revealed 55 unusual trades.</p>
<p>Delving into the details, we found 29% of traders were bullish, while 54% showed bearish tendencies. Out of all the trades we spotted, 27 were puts, with a value of $2,868,157, and 28 were calls, valued at $1,550,767.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $200.0 to $475.0 for Vertex Pharmaceuticals over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Vertex Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals's whale trades within a strike price range from $200.0 to $475.0 in the last 30 days. </p>
<h3>Vertex Pharmaceuticals Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506921_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/08/25</td>
<td>$87.4</td>
<td>$84.5</td>
<td>$87.11</td>
<td>$467.50</td>
<td>$941.8K</td>
<td align="right">176</td>
<td align="right">166</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$21.0</td>
<td>$20.5</td>
<td>$20.5</td>
<td>$380.00</td>
<td>$172.0K</td>
<td align="right">54</td>
<td align="right">30</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$8.8</td>
<td>$8.1</td>
<td>$8.0</td>
<td>$370.00</td>
<td>$140.0K</td>
<td align="right">113</td>
<td align="right">26</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/08/25</td>
<td>$88.5</td>
<td>$86.3</td>
<td>$86.3</td>
<td>$475.00</td>
<td>$138.9K</td>
<td align="right">307</td>
<td align="right">133</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/08/25</td>
<td>$87.6</td>
<td>$87.5</td>
<td>$87.5</td>
<td>$475.00</td>
<td>$113.7K</td>
<td align="right">307</td>
<td align="right">64</td>
</tr>
</tbody>
</table>
</p>
<h3>About Vertex Pharmaceuticals</h3>
<p>Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.</p>
<p>Having examined the options trading patterns of Vertex Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Vertex Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 3,551,703, the VRTX's price is up by 3.1%, now at $386.62. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 89 days.</li>
</ul>
<h3>Professional Analyst Ratings for Vertex Pharmaceuticals</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $459.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Showing optimism, an analyst from Wells Fargo upgrades its rating to Overweight with a revised price target of $460.<br />
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Vertex Pharmaceuticals with a target price of $530.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Vertex Pharmaceuticals with a target price of $439.<br />
&#x2A; Maintaining their stance, an analyst from Stifel continues to hold a Hold rating for Vertex Pharmaceuticals, targeting a price of $455.<br />
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Hold rating for Vertex Pharmaceuticals, targeting a price of $411. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


VRTX

Vertex Pharmaceuticals Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>First Solar</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with FSLR, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 47 uncommon options trades for First Solar.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 40% bullish and 42%, bearish.</p>
<p>Out of all of the special options we uncovered, 24 are puts, for a total amount of $1,704,421, and 23 are calls, for a total amount of $5,592,201.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $115.0 to $280.0 for First Solar over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in First Solar's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to First Solar's substantial trades, within a strike price spectrum from $115.0 to $280.0 over the preceding 30 days.</p>
<h3>First Solar Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506915_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$27.9</td>
<td>$25.95</td>
<td>$26.45</td>
<td>$250.00</td>
<td>$1.8M</td>
<td>7.8K</td>
<td>700</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$17.6</td>
<td>$15.65</td>
<td>$16.6</td>
<td>$250.00</td>
<td>$949.5K</td>
<td>1.5K</td>
<td>1</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$10.4</td>
<td>$9.85</td>
<td>$10.4</td>
<td>$260.00</td>
<td>$624.0K</td>
<td>6.0K</td>
<td>800</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$10.4</td>
<td>$9.85</td>
<td>$10.4</td>
<td>$260.00</td>
<td>$624.0K</td>
<td>6.0K</td>
<td>200</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/22/25</td>
<td>$4.15</td>
<td>$3.7</td>
<td>$4.15</td>
<td>$175.00</td>
<td>$556.5K</td>
<td>212</td>
<td>1.3K</td>
</tr>
</tbody>
</table>
</p>
<h3>About First Solar</h3>
<p>First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.</p>
<p>Having examined the options trading patterns of First Solar, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>First Solar's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,160,845, the price of FSLR is down by -0.18%, reaching $186.51.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for First Solar</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $219.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Susquehanna persists with their Positive rating on First Solar, maintaining a target price of $222.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on First Solar with a target price of $275.<br />
&#x2A; An analyst from Susquehanna persists with their Positive rating on First Solar, maintaining a target price of $203.<br />
&#x2A; An analyst from Jefferies has decided to maintain their Buy rating on First Solar, which currently sits at a price target of $194.<br />
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on First Solar with a target price of $203. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for First Solar with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


FSLR

First Solar's Options: A Look at What the Big Money is Thinking

<p>BlackRock TCP Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCPC#NASDAQ">TCPC</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-08-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that BlackRock TCP Cap will report an <strong>earnings per share</strong> (EPS) of $0.33.</p>
<p>BlackRock TCP Cap bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.02, leading to a 1.41% increase in the share price on the subsequent day.</p>
<p>Here's a look at BlackRock TCP Cap's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.34</td>
<td>0.37</td>
<td>0.39</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.36</td>
<td>0.36</td>
<td>0.36</td>
<td>0.38</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>0.0%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506907_0.png" alt="eps graph" /></p>
<h3>Market Performance of BlackRock TCP Cap's Stock</h3>
<p>Shares of BlackRock TCP Cap were trading at $7.17 as of August 05. Over the last 52-week period, shares are down 20.81%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TCPC/earnings"><strong>To track all earnings releases for BlackRock TCP Cap visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TCPC

What to Expect from BlackRock TCP Cap's Earnings

<p><strong>Spectrum Brands Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) is set to give its latest quarterly earnings report on Thursday, 2025-08-07. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Spectrum Brands Holdings will report an <strong>earnings per share</strong> (EPS) of $1.25. </p>
<p>The announcement from Spectrum Brands Holdings is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.73, leading to a 3.49% drop in the share price the following trading session.</p>
<p>Here's a look at Spectrum Brands Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.41</td>
<td>0.92</td>
<td>1.07</td>
<td>1.21</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.68</td>
<td>1.02</td>
<td>0.97</td>
<td>1.10</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>2.0%</td>
<td>-6.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506898_0.png" alt="eps graph" /></p>
<h3>Performance of Spectrum Brands Holdings Shares</h3>
<p>Shares of Spectrum Brands Holdings were trading at $54.21 as of August 05. Over the last 52-week period, shares are down 40.94%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analysts' Perspectives on Spectrum Brands Holdings</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Spectrum Brands Holdings.</p>
<p>A total of 3 analyst ratings have been received for Spectrum Brands Holdings, with the consensus rating being Buy. The average one-year price target stands at $71.67, suggesting a potential 32.21% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Energizer Hldgs, WD-40 and Reynolds Consumer Prods, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Energizer Hldgs, with an average 1-year price target of $27.44, suggesting a potential 49.38% downside.</li>
<li>Analysts currently favor an Buy trajectory for WD-40, with an average 1-year price target of $300.0, suggesting a potential 453.4% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Reynolds Consumer Prods, with an average 1-year price target of $22.75, suggesting a potential 58.03% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Energizer Hldgs, WD-40 and Reynolds Consumer Prods are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spectrum Brands Holdings</td>
<td>Buy</td>
<td>-5.96%</td>
<td>$253.40M</td>
<td>0.05%</td>
</tr>
<tr>
<td>Energizer Hldgs</td>
<td>Neutral</td>
<td>3.41%</td>
<td>$399.70M</td>
<td>96.81%</td>
</tr>
<tr>
<td>WD-40</td>
<td>Buy</td>
<td>1.21%</td>
<td>$88.11M</td>
<td>8.38%</td>
</tr>
<tr>
<td>Reynolds Consumer Prods</td>
<td>Neutral</td>
<td>0.86%</td>
<td>$226M</td>
<td>3.42%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Spectrum Brands Holdings ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is at the top for Return on Equity.</p>
<h3>Unveiling the Story Behind Spectrum Brands Holdings</h3>
<p>Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, global Pet Care, and Home and Garden. The Company manufactures, markets and distributes its products globally in the North America, Europe, Middle East &amp; Africa, Latin America, and Asia-Pacific.</p>
<h3>Spectrum Brands Holdings's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Spectrum Brands Holdings's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-5.96%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Spectrum Brands Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>0.13%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Spectrum Brands Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.05%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Spectrum Brands Holdings's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.03%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.38</strong>, Spectrum Brands Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/SPB/earnings"><strong>To track all earnings releases for Spectrum Brands Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Exploring Spectrum Brands Holdings's Earnings Expectations

<p>Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-08-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Sweetgreen will report an <strong>earnings per share</strong> (EPS) of $-0.08.</p>
<p>The announcement from Sweetgreen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS missed by $0.03 in the last quarter, leading to a 16.18% drop in the share price on the following day.</p>
<p>Here's a look at Sweetgreen's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.18</td>
<td>-0.18</td>
<td>-0.13</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.21</td>
<td>-0.25</td>
<td>-0.18</td>
<td>-0.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-16.0%</td>
<td>0.0%</td>
<td>-6.0%</td>
<td>33.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506889_0.png" alt="eps graph" /></p>
<h3>Performance of Sweetgreen Shares</h3>
<p>Shares of Sweetgreen were trading at $12.46 as of August 05. Over the last 52-week period, shares are down 53.51%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Insights on Sweetgreen</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Sweetgreen.</p>
<p>The consensus rating for Sweetgreen is Neutral, based on 16 analyst ratings. With an average one-year price target of $19.62, there's a potential 57.46% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Arcos Dorados Holdings, Cracker Barrel Old and First Watch Restaurant Gr, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Arcos Dorados Holdings, with an average 1-year price target of $8.8, suggesting a potential 29.37% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Cracker Barrel Old, with an average 1-year price target of $57.14, suggesting a potential 358.59% upside.</li>
<li>Analysts currently favor an Buy trajectory for First Watch Restaurant Gr, with an average 1-year price target of $21.75, suggesting a potential 74.56% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Arcos Dorados Holdings, Cracker Barrel Old and First Watch Restaurant Gr are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sweetgreen</td>
<td>Neutral</td>
<td>5.36%</td>
<td>$29.69M</td>
<td>-5.70%</td>
</tr>
<tr>
<td>Arcos Dorados Holdings</td>
<td>Neutral</td>
<td>-0.44%</td>
<td>$119.71M</td>
<td>2.72%</td>
</tr>
<tr>
<td>Cracker Barrel Old</td>
<td>Neutral</td>
<td>0.49%</td>
<td>$269.09M</td>
<td>2.70%</td>
</tr>
<tr>
<td>First Watch Restaurant Gr</td>
<td>Buy</td>
<td>16.41%</td>
<td>$48.77M</td>
<td>-0.14%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Sweetgreen ranks at the top for Revenue Growth among its peers. It is at the bottom for Gross Profit and Return on Equity.</p>
<h3>Get to Know Sweetgreen Better</h3>
<p>Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.</p>
<h3>Key Indicators: Sweetgreen's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Sweetgreen's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>5.36%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-15.06%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-5.7%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Sweetgreen's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-2.96%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Sweetgreen's debt-to-equity ratio is below the industry average at <strong>0.76</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/SG/earnings"><strong>To track all earnings releases for Sweetgreen visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Exploring Sweetgreen's Earnings Expectations

<p>Throughout the last three months, 11 analysts have evaluated Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $44.73, a high estimate of $58.00, and a low estimate of $37.00. This current average reflects an increase of 3.59% from the previous average price target of $43.18. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506882_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Devon Energy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$43.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Devon Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Devon Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Devon Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Devon Energy's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DVN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Devon Energy analyst ratings.</strong></a></p>
<h2>Delving into Devon Energy's Background</h2>
<p>Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. At the end of 2024, Devon reported net proved reserves of 2.2 billion barrels of oil equivalent. Net production averaged roughly 848,000 barrels of oil equivalent per day in 2024 at a ratio of 73% oil and natural gas liquids and 27% natural gas.</p>
<h3>Devon Energy's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Devon Energy's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>23.8%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>11.1%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Devon Energy's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>3.4%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Devon Energy's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>1.61%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Devon Energy's debt-to-equity ratio is below the industry average at <strong>0.62</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Where Devon Energy Stands With Analysts

<p>4 analysts have expressed a variety of opinions on SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated SEMrush Hldgs and provided 12-month price targets. The average target is $10.5, accompanied by a high estimate of $12.00 and a low estimate of $9.00. This current average represents a 28.81% decrease from the previous average price target of $14.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754506871_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive SEMrush Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Merwin</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to SEMrush Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of SEMrush Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for SEMrush Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of SEMrush Hldgs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SEMR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on SEMrush Hldgs analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know SEMrush Hldgs Better</h2>
<p>SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.</p>
<h3>Unraveling the Financial Story of SEMrush Hldgs</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining SEMrush Hldgs's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>3.69%</strong> as of 30 June, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> SEMrush Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-6.03%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> SEMrush Hldgs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-2.4%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-1.56%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.05</strong>, SEMrush Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SEMR

Analyst Expectations For SEMrush Hldgs's Future

<p>Cryptocurrency markets are trading higher on Wednesday despite an additional 25% tariff on India announced by President Trump.</p>
<p><figure class="wp-block-table"><br />
<table class="has-fixed-layout">
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Ticker</strong></td>
<td><strong>Price</strong></td>
</tr>
<tr>
<td><strong>Bitcoin</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$115,350.8</td>
</tr>
<tr>
<td><strong>Ethereum</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,676.65</td>
</tr>
<tr>
<td><strong>Solana</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$168.60</td>
</tr>
<tr>
<td><strong>XRP</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.99</td>
</tr>
<tr>
<td><strong>Dogecoin</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2057</td>
</tr>
<tr>
<td><strong>Shiba Inu</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001236</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Notable Statistics:</strong></p>
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction decreased by 11.8% and 19.1%, respectively. Daily active addresses grew 8.3% and 1.3%, respectively.</li>
<li>Coinglass data shows 106,013 traders were liquidated in the past 24 hours for $210.07 million. &nbsp;&nbsp;</li>
<li>The top losers in the 24 hours include <strong>Mantle</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MNT</a>), <strong>MemeCore</strong> (CRYPTO: M) and <strong>Story</strong> (CRYPTO: IP).</li>
</ul>
<p><strong>Notable Developments:</strong></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/08/46907896/how-a-bot-is-bringing-solana-ethereum-base-bnb-chain-trading-to-telegram">How A Bot Is Bringing Solana, Ethereum, Base, BNB Chain Trading To Telegram</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/08/46901218/would-you-take-your-salary-in-crypto-75-of-gen-z-say-yes">Would You Take Your Salary In Crypto? 75% Of Gen Z Say Yes</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/08/46894080/bitcoin-back-above-114000-is-the-bottom-in">Bitcoin Back Above $114,000: Is The Bottom In?</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/08/46888767/dp-world-tour-nexo-introduce-50000-crypto-prize-for-course-record-at-nexo-championship">DP World Tour, Nexo Introduce $50,000 Crypto Prize For Course Record At Nexo Championship</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/08/46904223/satsuma-raises-217m-aims-to-become-the-uks-largest-bitcoin-treasury-company">Satsuma Raises $217M, Aims To Become The UK&#8217;s Largest Bitcoin Treasury Company</a></li>
</ul>
<p><strong>Trader Notes: </strong>PlanB <a href="https://x.com/100trillionUSD/status/1953157401663668705">highlighted</a> that Bitcoin&#8217;s realized cost price is now $51,000, while the 2-year and 6-month realized prices stand at $88,000 and $104,000, respectively, all of which are trending upward. </p>
<p>With BTC trading at $115,000, it remains firmly above all realized price levels, signaling continued strength and no sign of weakness. </p>
<p>He reaffirmed that the bull market is intact and advancing.</p>
<p>CryptoCon pointed out that Bitcoin is still trading within healthy Detrended Price Oscillator (DPO) support zones and has not yet touched local highs or cycle top zones during this run.</p>
<p>His takeaway: the uptrend is strong, and there&#8217;s still plenty of room for upside. "Just keep riding it," he says.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Bitcoin at 115k is still registering as support on relative DPO zones.<br /><br />No moves to the local high zone, and no moves to the cycle top zone this entire cycle!<br /><br />So it&#39;s simple, we just keep on keeping on <a href="https://t.co/8DDT6Qcj6x">pic.twitter.com/8DDT6Qcj6x</a></p>
<p>&mdash; CryptoCon (@CryptoCon_) <a href="https://twitter.com/CryptoCon_/status/1953136301294719077?ref_src=twsrc%5Etfw">August 6, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Rekt Capital <a href="https://x.com/rektcapital/status/1953148271494308186">turned</a> attention to the critical $117,200 level, emphasizing that whether BTC reclaims it as support or faces rejection will shape the next move. </p>
<p>Given the cycle's pattern of downside deviations, he notes that a successful reclaim remains well within reach.</p>
<p>CJ advised traders to stay focused on key market metrics, particularly those that can signal trend shifts or momentum fades.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">As a price action maxi, I don&#39;t often look at metrics, but this stood out to me. <br /><br />Perhaps something to keep an eye on in the future. <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> <a href="https://t.co/t7CmZCzmsl">pic.twitter.com/t7CmZCzmsl</a></p>
<p>&mdash; CJ (@CJ900X) <a href="https://twitter.com/CJ900X/status/1953113694059036768?ref_src=twsrc%5Etfw">August 6, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/crypto/cryptocurrency/25/08/46907041/tom-lee-ethereum-is-having-a-2017-bitcoin-moment-could-hit-15000-by-end-of-2025">Tom Lee: Ethereum Is Having A &#8216;2017 Bitcoin Moment&#8217;, Could Hit $15,000 By End Of 2025</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$MNT

$SHIB

$SOL

$XRP

Bitcoin Inches Toward $115,000 As Ethereum, XRP, Dogecoin Hold Ground

Press Releases

Performant Healthcare, Inc. Announces Financial Results for First Quarter 2025

Performant to Participate in B Riley Securities' 25th Annual Institutional Investor Conference

Performant Healthcare, Inc. to Report Second Quarter 2025 Earnings on August 5, 2025

Performant Healthcare, Inc. to Be Acquired by Machinify

Performant Healthcare, Inc. Announces Preliminary Financial Results for Second Quarter 2025

PHLT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Performant Healthcare, Inc. Is Fair to Shareholders

Shareholder Alert: The Ademi Firm investigates whether Performant Healthcare Inc. is obtaining a Fair Price for its Public Shareholders

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PHLT, SNV, DALN on Behalf of Shareholders

PERFORMANT HEALTHCARE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Performant Healthcare, Inc. - PHLT

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PHLT, AMWD, MBC on Behalf of Shareholders

AMWD

DALN

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Tangible Equity Unit

BrightSpring Health

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Performant Healthcare

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO